Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01779869 · ClinicalTrials.gov registry record · Phase 4
Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson
A Phase 4 study of Ischemic Heart Disease, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT01779869 is a Phase 4 study of Ischemic Heart Disease that has completed, run by Washington University School of Medicine. The registered enrollment target is 16 participants, below the 265-participant average among 14 other Ischemic Heart Disease trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01779869, a Phase 4 study of Ischemic Heart Disease, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective for this pilot study is to develop an optimized, clinically usable myocardial PET-MR perfusion protocol and to determine which of all data potentially available should be acquired for a clinical myocardial perfusion examination. Hypothesis: The hypothesis is that high resolution, high sensitivity DCE MRI could replace the rest PET myocardial perfusion imaging, significantly decreasing examination time and patient radiation dose while maintaining the comprehensive reference-quality PET myocardial stress perfusion coverage. The primary outcome will be comparison of diagnostic accuracy of each combination of imaging to detect clinically significant coronary artery stenosis (≥70% diameter stenosis).
Conditions Studied
Interventions
- DRUG Regadenoson
Study Locations (1)
Missouri
- Center for Clinical Imaging Research at Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2013-01 |
| Est. Completion | 2015-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01779869
The ClinicalTrials.gov registry entry for NCT01779869 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 265-participant average among 14 other Ischemic Heart Disease trials with a reported enrollment target (94% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ischemic Heart Disease appearing as the primary indexed condition, and to 1 intervention - of which Regadenoson is the first listed.
NCT01779869 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT01779869 about?
NCT01779869 is a clinical study titled "Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson". The objective for this pilot study is to develop an optimized, clinically usable myocardial PET-MR perfusion protocol and to determine which of all data potentially available should be acquired for a clinical myocardial perfusion examination. Hypothesis: The hypothesis is that high resolution, high ...
What is the current status of trial NCT01779869?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2013-01. Estimated completion is 2015-06.
What conditions does trial NCT01779869 study?
This clinical trial studies the following conditions: Ischemic Heart Disease.
What interventions are being tested in trial NCT01779869?
The interventions under investigation include: Regadenoson (DRUG).
Who is sponsoring clinical trial NCT01779869?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01779869 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ischemic Heart Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
RECRUITING
-
Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
RECRUITING
-
Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia
RECRUITING · NA
-
Single or Repeated Intravenous Administration of umbiliCAl Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy
RECRUITING · Phase 2
-
Use of GeriKit to Better Phenotype Older Adults With Ischemic Heart Disease
RECRUITING · NA
-
Development of CIRC Technologies
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.